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Inducible nitric oxide synthase (iNOS) helps drive numerous inflammatory disorders, but its inhibi-
tion has not had therapeutic success. NowSeimetz et al. (2011)make a case for inhibiting iNOS in an
effort to treat one of the world’s leading causes of death—chronic obstructive pulmonary disease.In 1992, the gas nitric oxide (NO) was
crowned ‘‘molecule of the year’’ by
Science magazine. In the same year, the
high-output isoform of NO synthase
(which generates orders of magnitude
more NO than other isoforms) was cloned
and named ‘‘iNOS’’ for its inducibility by
inflammatory and immunologic stimuli
and independence of elevated intracel-
lular calcium (Xie et al., 1992). iNOS went
on to enjoy success in two arenas: linguis-
tics and pathophysiology. Linguistically,
iNOS called forth iPSCs from cell biolo-
gists and iNKT cells and iTregs from im-
munologists, as well as an array of ‘‘iPro-
ducts’’ from the technology sector. In
pathophysiology, the enzyme was found
to play prominent roles in many settings,
from endotoxic shock (MacMicking et al.,
1995) to host defense (Nathan and Shiloh,
2000), and now the literature includes
nearly 25,000 articles dealing with iNOS.
However, in the arena of therapeutics,
iNOS did not catch fire. The proinflamma-
tory roles of iNOS (Bogdan, 2001) made it
a choice target. Disappointingly, though,
no marked clinical benefits have emerged
from blocking iNOS in septic shock, asth-
ma, or other conditions, despite the de-
velopment of progressively more selec-
tive inhibitors that spare the other NOS
isoforms, nNOS (NOS1) and eNOS
(NOS3). Now, 20 years after iNOS was
first purified, new findings suggest that
its therapeutic inhibition deserves a fresh
look. Among these findings, Seimetz
et al. report in this issue of Cell the re-
markable observation that disrupting or
inhibiting iNOS prevented or reversed im-
portant manifestations of chronic ob-
structive pulmonary disease (COPD) in
mice (Seimetz et al., 2011).
The World Health Organization warns
that COPD may become the third leading
cause of death by 2030. In 2005, morethan 80 million people suffered from the
disease, and 3 million succumbed. The
chief cause of COPD is inhalation of
smoke from tobacco and cooking fires
and of air pollutants from automotive
and industrial activities. Prominent forms
of the disease include chronic bronchitis
(i.e., inflammation of the larger airways)
and emphysema (i.e., destruction of the
alveoli, or air sacs). Some patients also
have pulmonary hypertension (i.e., high
pressure in the pulmonary artery), which
can lead to heart failure. COPD is incur-
able except by lung transplantation, and
there is no therapy to halt its progression.
The inadequate treatment options and the
numerous interventions under consider-
ation (Barnes and Stockley, 2005) point
to gaps in our understanding of COPD’s
pathophysiologic mechanisms.
Now research from the Weissmann
group (Seimetz et al., 2011) brightens
this gloomy picture. When the authors
exposed mice to tobacco smoke for up
to 8 months, the lungs of the mice resem-
bled those of patients with advanced
COPD, including loss of alveoli, elastic
fibers, and small blood vessels. The lungs
of the mice also displayed thickening of
the remaining vessels, increased iNOS in
smooth muscle, decreased eNOS, and
increased protein nitration—additional
features found in patients with COPD.
Use of a mouse model allowed three
major insights into the pathogenesis of
COPD. First, smoke exposure caused
emphysema and pulmonary hypertension
in wild-type mice and in mice lacking
eNOS, but not in mice lacking iNOS.
Moreover, when the authors administered
an iNOS inhibitor after 8 months of smoke
exposure, the treatment reversed the lung
damage within 3 months. Second, the
smoke’s effects on pulmonary vascula-
ture and pulmonary arterial pressureCell 147preceded those on airways and were not
attributable to hypoxia. Third, bone mar-
row transplantation experiments demon-
strated that emphysema depended on
iNOS expression in radiation-resistant,
nonhematopoietic cells, but pulmonary
hypertension required expression of iNOS
in cells derived from the bone marrow.
These findings raise new questions about
the chain of causality in COPD. They also
commend iNOS inhibition as an experi-
mental therapy.
Renewed interest in therapeutic inhibi-
tion of iNOS is emerging in other settings
as well (Figure 1). Although the first bio-
logic effect that could be attributed in
retrospect to an action of iNOS was killing
of tumor cells (Hibbs et al., 1987), iNOS
can also promote tumor growth. Two
recent examples are noteworthy. Human
glioma stem cells depend on iNOS for
their proliferation and tumorigenicity, and
administration of an iNOS inhibitor that
crosses the blood-brain barrier retarded
the growth of human glioma grafts in the
brains of mice (Eyler et al., 2011). iNOS
is also expressed in inflammatory cells
that infiltrate mouse and human tumors.
iNOS produces NO from arginine. When
arginase is present, arginine is limiting,
and iNOS begins to generate superoxide
in addition to NO. These two radicals
can react to form peroxynitrite, which
can nitrate proteins. A recent study in
mice showed that iNOS-dependent nitra-
tion of the chemokine CCL2 forestalled
the entry of cytolytic T cells into the tumor
(Molon et al., 2011). Inhibiting peroxyni-
trite generation by iNOS markedly im-
proved immunologic control of the tumors
(Molon et al., 2011).
Should clinical investigators rush to test
iNOS inhibitors in patients with emphy-
sema, especially those with pulmonary
hypertension? This depends on the, October 14, 2011 ª2011 Elsevier Inc. 257
Figure 1. Three Potential Settings for Therapeutically Targeting
iNOS
Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO), contributing
to the formation of peroxynitrite (OONO) (center). Diverse and sometimes
opposing functional effects (inner circle) result from a large number of specific
molecular modifications, a few of which are illustrated in the outer ring. For
instance, in the lungs of mice with emphysema, iNOS increased the level of
Bax and matrix metalloproteinase 9 (Mmp9) but decreased the level of tissue
inhibitor of matrix metalloproteinase 3 (Timp3). In tumors, iNOS contributed to
nitration of CCL2 (C-C chemokine ligand 2, also called monocyte chemotactic
protein 1). CDA1 is an abbreviation for cell-cycle inhibitor cell division auto-
antigen.meaning of ‘‘rush.’’ Highly
specific iNOS inhibitors with
suitable pharmaceutical pro-
perties are at hand. However,
their experimental use in em-
physema should be initiated
only when key criteria are
met. Subjects need to be ap-
propriately phenotyped and
stratified, so that patients
with similar types of emphy-
sema at similar stages of se-
verity are equally represented
in the experimental and con-
trol groups. Appropriate bio-
markers need to be selected
to allow proof of mechanism.
Appropriate endpoints should
be included such that proof
of concept need not depend
solely on rates of mortality.
Finally, mechanisms should
be in place to monitor safety.
It will be particularly important
to exclude patients with sub-
clinical infections, such as
tuberculosis, which iNOS
may help control (Nathan
and Shiloh, 2000). iNOS can
inhibit proliferation of T cells
(Bogdan, 2001). Thus, it will
also be important to watch
for the possible expansion of
the oligoclonal populationsof T cells whose presence in the lungs of
some patients with COPD suggests reac-
tivity against a limited set of antigens, as
seen in autoimmune diseases (Cosio
et al., 2009).
Activation of iNOS in diverse contexts
can lead to opposite outcomes. For
example, iNOS promotes glioma stem
cell proliferation but suppresses prolifera-258 Cell 147, October 14, 2011 ª2011 Elsevition of T cells. Such conflicting actions
may help explain why iNOS inhibitors
have not yet been beneficial in the clinic.
Another possible explanation is that
mice often fail to model humans suffi-
ciently to predict the outcome of an
experimental intervention. For example,
it is far from clear whether humans have
the robust capacity to regenerate lunger Inc.tissues that Seimetz and
colleagues observed in mice.
Notwithstanding such con-
cerns, the new findings are
likely to spur clinical trials
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